Position in NVCT
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$317,613
+$250,695 QoQ
Shares Held
17,271
+99.5% QoQ
Ownership
0.053%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#38
of 82 holders
Holding Since
Jun 2023
10 quarters on record
Voting authority
Sole 24%
Shared 0%
None 76%
Common Shares in NVCT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026RHUMBLINE ADVISERS holds $1,414,750,230 across 329 Biotechnology names. NVCT ranks #217 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
396,380 | $196,893,837 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
157,794 | $98,390,870 | |
| 3 | MRNA |
Moderna, Inc.
|
809,853 | $56,714,005 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
165,579 | $49,844,246 | |
| 5 | INCY |
Incyte Corp
|
428,533 | $48,578,500 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
226,008 | $42,326,778 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
1,178,789 | $41,717,342 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
163,018 | $39,282,447 |
All Filings in NVCT
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $317,613 | 17,271 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $66,918 | 8,657 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $63,669 | 8,433 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $68,206 | 11,330 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $94,704 | 12,678 | Shares | Sole | 2025-08-12 | |
| 2024-06-30 | $11,843 | 1,871 | Shares | Sole | 2024-08-01 | |
| 2024-03-31 | $61,516 | 7,502 | Shares | Sole | 2024-05-09 | |
| 2023-12-31 | $60,656 | 7,273 | Shares | Sole | 2024-02-08 | |
| 2023-09-30 | $93,748 | 7,273 | Shares | Sole | 2023-11-09 | |
| 2023-06-30 | $108,244 | 6,778 | Shares | Sole | 2023-08-08 | |
| No filing history on record for this holder in this stock. | ||||||